# Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD

> **NCT07425210** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Chronic Obstructive Lung Disease (COLD)

## Interventions

- **DRUG:** HSK39004 Dry Powder Inhaler -0.75mg BID

## Key facts

- **NCT ID:** NCT07425210
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-07
- **Final completion:** 2027-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425210, "Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07425210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*